Last week, Professor Brook Baker filed an Amicus Brief responding to four of the arguments made by Pfizer against the compulsory license requested by KEI in the Dominican Republic to allow the distribution of the generic version of Paxlovid. His… Continue Reading
On Friday, December 3, 2021, KEI requested an open public interest license to allow the exploitation of PF-07321332 (marketed in combination with ritonavir under the brand Paxlovid) in the Dominican Republic. PF-07321332, being developed by Pfizer, has shown promising results… Continue Reading
(For more resources, please see our page on molnupiravir.) KEI has built a dataset of patents related to molnupiravir based upon a study by Imran et al (2021), the Medicines Patent Pool (MPP) MedsPal database, and our own searches. Our… Continue Reading
(For more resources, please see our page on molnupiravir.) Molnupiravir, the oral pill that is showing promising results as a potential treatment for covid-19, was invented at Emory University with U.S. government funds. After more than six years of non-clinical… Continue Reading
On 12 May 2021, Antigua and Barbuda notified the World Trade Organization (WTO) of their general intent to use the compulsory license system provided under article 31bis of the amended Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). This… Continue Reading
Today the government of Bolivia and Biolyse, a company based in Canada, signed an agreement to acquire COVID-19 vaccines manufactured by the company, if Canada grants them a compulsory license. Biolyse is a manufacturer of cancer drugs with the potential… Continue Reading
Allele is accusing Pfizer and BioNTech of infringing one of their patents during the research that led to their COVID-19 vaccine, according to a complaint recently filed in a federal court in California, United States. The case relates to U.S.… Continue Reading
PDF version here:LGA-NIST-Subject-Invention-definition-26March2021 More on the NIST proposed changes to the Bayh-Dole Regulations. https://www.keionline.org/35432 Comments of Luis Gil Abinader of Knowledge Ecology International on the redefinition of “Subject Invention” to Narrow the Inventions to Which Government Rights Attach (Modify 37… Continue Reading
On February 25, 2021, the intellectual property office in Ecuador granted a compulsory license over a patent directed to the raltegravir active ingredient. Raltegravir, commonly marketed under the brand name Isentress, is used to treat HIV infections. The licensed patent… Continue Reading
On March 1, 2021, KEI obtained a copy of the binding term sheet between Pfizer/BioNTech and the Dominican Republic for the supply of their COVID-19 vaccine in the country. The document, requested via the freedom of information law in the… Continue Reading